What's Happening?
Karyopharm Therapeutics is seeking to expand the use of its blood cancer drug Xpovio to treat myelofibrosis, despite mixed results from a pivotal trial. The SENTRY trial showed that Xpovio, when combined with Jakafi, significantly reduced spleen volume
in patients but did not significantly improve total symptom scores. Karyopharm plans to discuss the trial's data with the FDA, highlighting a trend towards improved overall survival. Xpovio is already approved for multiple myeloma and diffuse large B-cell lymphoma, contributing significantly to Karyopharm's revenue. The company is also exploring Xpovio's potential in treating endometrial cancer.
Why It's Important?
The potential approval of Xpovio for myelofibrosis could provide a new treatment option for a condition with limited therapies. Current treatments, primarily JAK inhibitors, have modest effects and can cause serious side effects. Xpovio's ability to reduce spleen volume, a key treatment goal, could improve patient outcomes and survival rates. This development is crucial for Karyopharm's growth strategy, as expanding Xpovio's indications could enhance its market presence and financial stability. The mixed trial results have affected investor confidence, reflected in a decline in Karyopharm's share price.
What's Next?
Karyopharm will engage with the FDA to discuss the possibility of filing for Xpovio's approval for myelofibrosis based on the trial's data. The company is also conducting a phase 3 trial for Xpovio in endometrial cancer, with results expected later this year. Financially, Karyopharm has secured a $30 million private placement to extend its operational funding into late Q3, which will support ongoing research and development efforts.
